Gregory Ho
President and Chief Operating Officer @ Spring Mountain Capital
New York, United States
Gregory Ho is a Series A investor at Spring Mountain Capital in New York focused on Health Care and Therapeutics. Gregory Ho has served as the President and Chief Operating Officer of SMC since its founding in June 2001. Previously, he was a Principal and Chief Financial Officer of McKinsey & Company, Inc. During his 16 years with McKinsey, he led the financial and tax planning for the firm and its worldwide partner group, as well as the identification,evaluation, and selection of traditional and alternative asset managers for over $1 billion of assets in its qualified employee plans and in-house investment office. Gregory Ho was also a Trustee of McKinsey's Profit-Sharing Retirement Plan and a member of the firm's Investment Committee. After leaving McKinsey in 1998 and prior to joining SMC, Gregory Ho was a private investor and consultant. Prior to joining McKinsey, he was associated with the law firm of Donovan Leisure Newton & Irvine. Gregory Ho received a J.D. from Columbia Law School and a B.S., with honors, in Administrative Science from Yale College. He is a member of the New York Bar and the California Bar.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Gregory Ho invests in
Stages Gregory Ho invests in
Countries Gregory Ho invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (33%)
- Therapeutics 2 (33%)
- Biotechnology 2 (33%)
- Catering 1 (17%)
- Hospitality 1 (17%)
Stage
- Series A 2 (33%)
- Seed 1 (17%)
- Series B 1 (17%)
- Series C 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions.The company was founded in 2013 and is headquartered in Branford, Connecticut. | Series C / Jan 09, 2020 | ||
| IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions.The company was founded in 2013 and is headquartered in Branford, Connecticut. | Series C / May 14, 2019 | ||
| Founded in 2015, junzi grew out of a hunger for our childhood staples: northern Chinese food made with healthy, seasonal ingredients. Yet recreating the taste of home has done much more than sate our cravings—the amazing power of food in building community has inspired us to make our bings and noodles accessible to all. In just three years,we’ve grown junzi to four locations in New Haven, CT near Yale University, Morningside Heights near Columbia University, Greenwich Village near NYU and (soon-to-open) Bryant Park—and that’s just the beginning! | $1.8M / Seed / Aug 01, 2018 | ||
| ReNetX Bio first-in-class therapeutics to treat injury and damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI)and glaucoma. | Series A / May 07, 2018 | ||
| IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions.The company was founded in 2013 and is headquartered in Branford, Connecticut. | $13.5M / Series B / Sep 25, 2017 | ||
| IsoPlexis is a life science technology company developing a single-cell detection system that identifies a wide range of patient immune responses at the single-cell level. Its platform can assess the safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development, and informing physician decisions.The company was founded in 2013 and is headquartered in Branford, Connecticut. | $1.3M / Series A / Aug 12, 2014 |
Co-Investors
About Spring Mountain Capital
Spring Mountain Capital focuses on providing expansion capital to companies capitalizing on breakthrough innovations, paradigm shifts, or fundamental market or behavioral changes. SMC invests in sectors of the U.S. economy undergoing the most change and with the highest growth potential: enterprise software, technology-enabled services, digitalhealth, and healthcare services.
Spring Mountain Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Gregory Ho
President and Chief Operating Officer
|
|||
Jamie Weston
Managing Director
|
|||
John Gu
Principal
|
|||
John Steffens
Founder & Senior Managing Director
|
|||
Kenneth Soll
Vice President
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Gregory Ho invest in?
Gregory Ho invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Gregory Ho?
Public channels for Gregory Ho include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Gregory Ho last invest?
The most recent investment recorded for Gregory Ho closed in Jan 2020. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
